Literature DB >> 18627572

New insights of HLA class I association to Behçet's disease in Portuguese patients.

A Bettencourt1, C Pereira, L Carvalho, C Carvalho, J V Patto, M Bastos, A M Silva, R Barros, C Vasconcelos, P Paiva, L Costa, P P Costa, D Mendonça, J Correia, B M Silva.   

Abstract

Human leukocyte antigen (HLA)-B*51 is a well-known genetic factor associated with Behçet's disease (BD). To analyse the influence of HLA-B*51 and other HLA class I alleles in BD susceptibility in a Portuguese population and its association with disease severity, we studied 78 BD patients and 208 healthy controls. The patients were classified into two severity groups as described by Gul et al. As expected, a higher frequency of HLA-B*51 was found. The frequency of HLA-Cw*16 alleles was significantly higher in patients. Regarding severity, HLA-B*27 frequency was higher in the severe group compared with controls and with the mild group. Thus, HLA-B*51 and HLA-Cw*16 seem to confer susceptibility to BD in this patients. HLA-B*27 may be important as a prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627572     DOI: 10.1111/j.1399-0039.2008.01087.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  8 in total

1.  Beyond Human Leukocyte Antigen Class I Antigens: Hereditary Hemochromatosis Gene Mutations in Recurrent Aphthous Oral Ulcers and Behçet Disease in the South of Tunisia.

Authors:  Sahar ElAoud; Arwa Kamoun; Nadia Mahfoudh; Aida Charfi; Mouna Snoussi; Hend Hachicha; Ameni Jerbi; Chifa Dammak; Feten Frikha; Faiza Hakim; Lilia Gaddour; Zouheir Bahloul; Hafedh Makni
Journal:  Med Princ Pract       Date:  2017-09-26       Impact factor: 1.927

Review 2.  Juvenile spondyloarthropathies.

Authors:  R Hal Scofield; Andrea L Sestak
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

3.  Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease.

Authors:  Travis Hughes; Patrick Coit; Adam Adler; Vuslat Yilmaz; Kenan Aksu; Nursen Düzgün; Gokhan Keser; Ayse Cefle; Ayten Yazici; Andac Ergen; Erkan Alpsoy; Carlo Salvarani; Bruno Casali; Ina Kötter; Javier Gutierrez-Achury; Cisca Wijmenga; Haner Direskeneli; Güher Saruhan-Direskeneli; Amr H Sawalha
Journal:  Nat Genet       Date:  2013-02-10       Impact factor: 38.330

4.  Behçet disease, new insights in disease associations and manifestations: a next-generation sequencing study.

Authors:  M Elfishawi; G Mossallam; D G Augusto; G Montero-Martin; H de Bruin; L Van de Pasch; P J Norman; E Rozemuller; M Fernandez-Vina; A Abrudescu; J A Hollenbach; K Zaky; S Elfishawi
Journal:  Clin Exp Immunol       Date:  2021-02-03       Impact factor: 5.732

5.  A Case of Human Leukocyte Antigen (HLA) B27-Positive Intestinal Behçet's Disease with Crohn's Disease-Like Anal Fistulas.

Authors:  Tsuyoshi Kobashigawa; Yuki Nanke; Masakazu Takazoe; Kuniko Iihara; Hisashi Yamanaka; Shigeru Kotake
Journal:  Clin Med Insights Case Rep       Date:  2014-04-27

Review 6.  Immunopathogenesis of ocular Behçet's disease.

Authors:  Un Chul Park; Tae Wan Kim; Hyeong Gon Yu
Journal:  J Immunol Res       Date:  2014-07-02       Impact factor: 4.818

7.  New insights into HLA class I association to Behçet's syndrome in Iranian Azari patients.

Authors:  Fatemeh Zare Shahneh; Fatemeh Hamzavi; Babak Bayazi; Ali Bandehagh; Behzad Baradaran
Journal:  Auto Immun Highlights       Date:  2013-02-12

8.  HLA and non-HLA genes in Behçet's disease: a multicentric study in the Spanish population.

Authors:  Marco Antonio Montes-Cano; Marta Conde-Jaldón; José Raul García-Lozano; Lourdes Ortiz-Fernández; Norberto Ortego-Centeno; María Jesús Castillo-Palma; Gerard Espinosa; Genaro Graña-Gil; Miguel Angel González-Gay; Ana Celia Barnosi-Marín; Roser Solans; Patricia Fanlo; Teresa Camps; Santos Castañeda; Juan Sánchez-Bursón; Antonio Núñez-Roldán; Javier Martín; María Francisca González-Escribano
Journal:  Arthritis Res Ther       Date:  2013-10-04       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.